Types of IV iron preparations SEO Brief & AI Prompts

IV iron preparations include iron sucrose, ferric carboxymaltose, ferumoxytol, ferric gluconate, and iron dextran; they differ by allowable single‑dose and infusion time (for example, iron sucrose is commonly administered as 100–200 mg per dose, ferric carboxymaltose permits up to 750 mg in a single 15‑minute infusion in many regions, ferumoxytol is labeled as 510 mg administered twice for a 1,020 mg total, and iron dextran can be given as a 1,000 mg total‑dose infusion after a test dose). Selection between products is driven by total iron deficit, urgency of repletion, prior hypersensitivity, and local protocols. Cost, formulary restrictions, infusion capacity, and reimbursement policies frequently influence institutional selection and scheduling.

Intravenous iron delivers iron directly to the reticuloendothelial system, bypassing gastrointestinal absorption limits and enabling rapid transferrin loading for erythropoiesis; macrophages process the iron–carbohydrate complex and release iron bound to transferrin for marrow uptake. Clinical decision tools such as TSAT (transferrin saturation) and serum ferritin guide use; KDIGO, WHO, and NIH frameworks recommend using TSAT and ferritin thresholds to determine need for intravenous iron versus oral therapy. Different carbohydrate shells (sucrose, carboxymaltose, dextran, gluconate) influence labile plasma iron, infusion duration, and observation requirements. For iron deficiency anemia infusion planning, choice of product affects total‑dose calculation and monitoring frequency. Dose calculators and standardized pharmacy compounding and observation protocols are commonly implemented locally.

A frequent practical error is conflating oral failure with absence of IV need; specific IV iron indications differ by context. For non‑dialysis chronic kidney disease a commonly applied threshold is TSAT <20% with ferritin <100 ng/mL, whereas dialysis populations often use ferritin <200 ng/mL with TSAT <20% to prompt IV therapy. When rapid repletion is required (for example, preoperative anemia with surgery in 2–4 weeks), ferric carboxymaltose or ferumoxytol allows larger single‑session dosing than iron sucrose, changing iron infusion dosing decisions. IV iron safety considerations include differing hypersensitivity risk profiles (test doses typically reserved for iron dextran) and established pathways for iron infusion reaction management, and pregnancy considerations where relevant too. Clinicians should therefore pair lab thresholds with clinical urgency, bleeding status, and prior adverse reactions when selecting a product.

Practical application: calculate total iron deficit using a validated method (eg, Ganzoni formula) and select a preparation that matches the dose and speed required, balancing test‑dose requirements and allergy history. Monitor TSAT and ferritin before and 4–8 weeks after completion, observe for infusion reactions during and for 30 minutes after administration when using higher‑dose products, and document lot and product. Pharmacy verification, nursing checklists, and emergency equipment should be pre‑identified locally. This page provides a structured, step‑by‑step framework for formulation selection, dosing calculations, administration checklists, and emergency management protocols.